We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is partnering with the Massachusetts Institute of Technology (MIT) to develop new databases as part of a broad agency initiative to improve its postapproval monitoring of drugs, a high-ranking FDA official said.